Navigation Links
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Date:8/4/2009

PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication.

"We are delighted to have licensed the rights to this exciting new technology from Stanford University," said David Cory, President and CEO of Eiger. "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients."

"The unique two component nature of the NS4B-RNA target appears to decrease the virus' ability to escape inhibition by the small molecule inhibitors in development at Eiger, and that should decrease HCV resistance to this type of antiviral therapy," said Jeffrey Glenn. "These virus specific agents in development at Eiger possess the promise of more effective, oral drugs that can be essential components of all future cocktails for HCV therapy."

About Hepatitis C Virus

Infections from HCV have reached pandemic proportions, affecting over 150 million people worldwide. According to the Centers for Disease Control (CDC), 3.9 million Americans have been exposed to HCV, resulting in 2.7 million cases of chronic infection. Chronic HCV infection leads to serious liver disease (e.g. liver scarring and cirrhosis) and is the leading cause of liver cancer
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Eiger BioPharmaceuticals Raises $7.1 Million A Round
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
5. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
6. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
7. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
9. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
10. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
11. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... to Exceed $8 Billion Globally by 2012VENTURA, Calif., ... a continuous, integrated and wearable remote patient monitoring ... executive officer Howard Baker will present at the ... the Marines Memorial Club and Hotel in San ...
... 7 Nuvelo, Inc.,(Nasdaq: NUVO ) ... approved,the issuance of Nuvelo Common Stock pursuant to ... between Nuvelo, ARCA biopharma and a Nuvelo,subsidiary. Nuvelo,s ... until January 23, 2009, to solicit additional proxies ...
... settled in for the,winter months and since the common ... days of school and work, now is the time ... Immunity Enhanced Beverage is designed,to do just that. , ... Products, Immunity Enhanced,Beverage is a ready-to-drink liquid supplement intended ...
Cached Biology Technology:VivoMetrics to Present at the 2009 Biotech Showcase 2VivoMetrics to Present at the 2009 Biotech Showcase 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 4Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 5Innovative Beverage Products Launches New Product Designed to Enhance the Body's Immune Defense 2
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... Rochelle, NY, July 9, 2014Biofuels derived from the oils ... to fossil fuels. To achieve this goal, optimization of ... in open pond systems, is needed. Sapphire Energy has ... of open pond algae cultivation systems, described in ... Liebert, Inc., publishers. The article is available on the ...
(Date:7/9/2014)... The Cancer Genome Atlas (TCGA) Research Network have ... in lung adenocarcinoma, the most common subtype of ... expand the number of possible therapeutic targets for ... of patients with treatable mutations because many potent ... , TCGA is jointly funded and managed by ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... potentially life-threatening challenge characterized by pauses in breathing that ... prematurity (AOP) affects more than 50 percent of premature ... preemies. Caused in part by an underdeveloped central nervous ... womb, especially during sleep, AOP is not yet fully ...
... or the American Chemical Society as publisher of this report. ... time in the United States, researchers are reporting in a ... fresh and canned food as well as food wrapped in ... almost 1,000 times lower than the "tolerable daily intake" levels ...
... study by the team headed by Llus Ribas de Pouplana, ... Barcelona), has been chosen as "Paper of the week" in ... , which is already available online. The article describes the ... melanogaster (fruit fly) that is crucial for mitochondria. The ...
Cached Biology News:UMass Medical School study points to genetic link in apnea of prematurity 2Scientists at IRB Barcelona discover a new protein critical for mitochondria 2
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
...
Biology Products: